Stribild

Phase 3

Gilead Sciences, Inc. (GILD)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Acquired Immunodeficiency Syndrome

View Full Landscape

Drug Information

Target Indication

Acquired Immunodeficiency Syndrome

Clinical Trial

NCT01475838

Last updated: 1/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA5/24/2013

Stribild

Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

GILD

Gilead Sciences, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

ZimberelimabPhase 3

Head and Neck Squamous Cell Carcinoma

LenacapavirPhase 3

HIV Prevention